ramosetron

Known as: 5-((1-methyl-3-indolyl)carbonyl)-4,5,6,7-tetrahydro-1H-benzimidazol 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
BACKGROUND & AIMS Ramosetron, a serotonin (5-hydroxytryptamine)-3 receptor antagonist with high selectivity, reduced stress… (More)
Is this relevant?
2013
2013
Irritable bowel syndrome (IBS) is a functional disease with persisting gastrointestinal symptoms that has been classified into… (More)
  • table 1
Is this relevant?
2009
2009
Patients undergoing general anesthesia for laparoscopic cholecystectomy are at high risk for postoperative nausea and vomiting… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2002
Review
2002
Ramosetron is a selective serotonin 5-HT3 receptor antagonist with an affinity higher than that of the previously available drugs… (More)
Is this relevant?
2002
2002
OBJECTIVE To evaluate the efficacy and safety of ramosetron (a 5-hydroxytryptamine type 3 receptor antagonist) for the prevention… (More)
Is this relevant?
2002
2002
Control of nausea and vomiting is very important in determining patient compliance with cisplatin chemotherapy. A multicentre… (More)
Is this relevant?
2002
2002
BACKGROUND Postoperative nausea and vomiting (PONV) are common after thyroidectomy. Granisetron, a selective 5-hydroxytryptamine… (More)
Is this relevant?
2000
2000
UNLABELLED In a prospective, randomized, double-blinded, placebo-controlled trial, we evaluated the efficacy of ramosetron at… (More)
Is this relevant?
1999
1999
PURPOSE To compare the efficacy of ramosetron with granisetron for the prevention of postoperative nausea and vomiting (PONV… (More)
Is this relevant?
1999
1999
UNLABELLED In a prospective, randomized, double-blinded study, we evaluated the efficacy of granisetron and ramosetron for… (More)
Is this relevant?